Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, open-label phase 2b study to investigate the preliminary efficacy and safety of INNO-206 (Doxorubicin-EMCH) compared to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcoma

Next Previous
Trial Profile

A multicenter, randomized, open-label phase 2b study to investigate the preliminary efficacy and safety of INNO-206 (Doxorubicin-EMCH) compared to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldoxorubicin (Primary) ; Doxorubicin
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Sponsors CytRx Corporation; LadRx Corporation

    • Most Recent Events

    • 07 Jun 2018 According to a CytRx Corporation media release, pooled data from this and other study (700249151) were presented at the American Society of Clinical Oncology 2018 Annual Meeting.
    • 07 Jun 2018 Results presented in the CytRx Corporation media release.
    • 08 Jun 2017 According to a CytRx Corporation media release, data from this and another study Phase 3 (CTP700214726) will be used in NDA filing for aldoxorubicin in soft tissue sarcomas (STS).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top